Summary - CAMP - NASDAQ - Weiss Ratings

Development

E

Camp4 Therapeutics Corporation CAMP

$1.67 $0.031.83% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$3.01 - $12.30

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

AI Accessories Advertising Aerospace

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Here's Why Camp4 Therapeutics (NASDAQ:CAMP) Must Use Its Cash Wisely

7/2/2025 - Simply Wall St

Sequans Appoints Jason W. Cohenour to Board of Directors

6/30/2025 - Newsfile Corp. - News Releases

Camp4 Therapeutics (CAMP) Gains Analyst Support with Promising Treatment CAMP Stock News

5/27/2025 - GuruFocus

Wedbush Sees Bright Future for Camp4 Therapeutics (CAMP) with New Coverage CAMP Stock News

5/27/2025 - GuruFocus

Camp4 Therapeutics initiated with bullish view at Wedbush, here's why

5/27/2025 - The Fly

Camp4 Therapeutics initiated with bullish view at Wedbush

5/27/2025 - The Fly

Piper Sandler Keeps Their Buy Rating on CAMP4 Therapeutics Corporation (CAMP)

5/19/2025 - TipRanks Financial Blog

CAMP4 Therapeutics (CAMP) Highlights Promising Data from Gene Therapy Trials CAMP Stock News

5/16/2025 - GuruFocus

Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders

5/16/2025 - TipRanks Financial Blog

Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders

5/16/2025 - The Fly

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

5/16/2025 - Globe Newswire

Camp4 Therapeutics Corp Reports Q1 2025 Net Loss of $12.4 Million, Cash Reserves at $49.3 Million

5/15/2025 - GuruFocus

William Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)

5/14/2025 - TipRanks Financial Blog

Camp4 Therapeutics reports Q1 EPS (62c), consensus (70c)

5/13/2025 - The Fly

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

5/13/2025 - Globe Newswire

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

4/28/2025 - Globe Newswire

CAMP4 Therapeutics Advances RNA-Based Therapeutics

4/1/2025 - TipRanks Financial Blog

Camp4 Therapeutics Corp Reports 2024 Financial Results with $51. ...

3/29/2025 - GuruFocus

William Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)

3/28/2025 - TipRanks Financial Blog

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

3/27/2025 - Globe Newswire

Camp4 Therapeutics appoints Williams, Stewart to board of directors

3/18/2025 - The Fly

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

3/18/2025 - Globe Newswire

CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025

3/4/2025 - Insider Monkey

12 Penny Stocks with Insider Buying in 2025

3/4/2025 - Insider Monkey

CAMP4 to Participate in Upcoming Investor Conferences

2/6/2025 - Globe Newswire

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Thursday, March 27, 2025

Period Date

Tuesday, December 31, 2024

Next Filing

Week of Oct 6 and 10 (est)

Price History

Loading...

Beta

--

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

--

2-Year Total Return

--

3-Year Total Return

--

5-Year Total Return

--

52-week Low

Apr 04, 2025 - $3.01

52-week High

Oct 14, 2024 - $12.30

Valuation

Market Cap

$61.04M - Micro Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

www.camp4tx.com

Phone Number

(617) 651-8867

Address

One Kendall Square
Building 1400 West - 3rd Floor
Cambridge, MA 02139

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product... more